{
    "data": [
        {
            "id": "4228680",
            "type": "article",
            "attributes": {
                "publishOn": "2018-12-17T08:51:08-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly Moving From One End Of The Spectrum To The Other For Alzheimer's Treatment",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "1803",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4228680-eli-lilly-moving-from-one-end-of-spectrum-to-for-alzheimers-treatment"
            }
        },
        {
            "id": "4210509",
            "type": "article",
            "attributes": {
                "publishOn": "2018-10-08T14:49:36-04:00",
                "isLockedPro": false,
                "commentCount": 58,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly Surges On Pipeline News: Analysis And Trading Thoughts",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "20600",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4210509-eli-lilly-surges-on-pipeline-news-analysis-and-trading-thoughts"
            }
        },
        {
            "id": "4209262",
            "type": "article",
            "attributes": {
                "publishOn": "2018-10-01T22:57:13-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly Looks To Be A Strong Competitor In The Preventative Migraine Market",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "20395",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4209262-eli-lilly-looks-to-be-strong-competitor-in-preventative-migraine-market"
            }
        },
        {
            "id": "4200429",
            "type": "article",
            "attributes": {
                "publishOn": "2018-08-20T01:17:05-04:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Neuroscience In Big Pharma: Eli Lilly",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "64963",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "18745",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4200429-neuroscience-in-big-pharma-eli-lilly"
            }
        },
        {
            "id": "4198435",
            "type": "article",
            "attributes": {
                "publishOn": "2018-08-13T05:37:43-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Diabetes And Upcoming REWIND Data Key Topics Of Debate For Eli Lilly",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "78545",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "18493",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4198435-diabetes-and-upcoming-rewind-data-key-topics-of-debate-for-eli-lilly"
            }
        },
        {
            "id": "4198036",
            "type": "article",
            "attributes": {
                "publishOn": "2018-08-11T13:57:26-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly Is An Attractive Buy For 2018",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102293",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "18462",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4198036-eli-lilly-is-attractive-buy-for-2018"
            }
        },
        {
            "id": "4195616",
            "type": "article",
            "attributes": {
                "publishOn": "2018-08-07T04:35:37-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "PAINS Filters In The Real World",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20694",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4195616-pains-filters-in-real-world"
            }
        },
        {
            "id": "4179467",
            "type": "article",
            "attributes": {
                "publishOn": "2018-06-05T12:02:03-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Novo's Oral Semaglutide Not Such A Clear Win Over Eli Lilly's Jardiance",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103071",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4179467-novos-oral-semaglutide-not-clear-win-over-eli-lillys-jardiance"
            }
        },
        {
            "id": "4174654",
            "type": "article",
            "attributes": {
                "publishOn": "2018-05-16T11:24:22-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly Had Good Reason To Spend $1.6B On Armo",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "87856",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4174654-eli-lilly-good-reason-to-spend-1_6b-on-armo"
            }
        },
        {
            "id": "4174585",
            "type": "article",
            "attributes": {
                "publishOn": "2018-05-16T07:38:26-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly's Positive Phase 3 Results Along With Recent Acquisitions Makes It A Force To Be Reckoned With",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4174585-eli-lillys-positive-phase-3-results-along-recent-acquisitions-makes-force-to-be-reckoned"
            }
        },
        {
            "id": "4172727",
            "type": "article",
            "attributes": {
                "publishOn": "2018-05-11T00:49:47-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly Makes A Bold Acquisition; How Lucrative Is It?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "15066",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4172727-eli-lilly-makes-bold-acquisition-how-lucrative-is"
            }
        },
        {
            "id": "4171562",
            "type": "article",
            "attributes": {
                "publishOn": "2018-05-08T23:51:47-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Is It Wise To Pick Up Eli Lilly In 2018?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102293",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "14978",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4171562-why-is-wise-to-pick-up-eli-lilly-in-2018"
            }
        },
        {
            "id": "4157688",
            "type": "article",
            "attributes": {
                "publishOn": "2018-03-20T03:18:33-04:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly Gets Another Crack At FDA Approval For RA Drug",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4157688-eli-lilly-gets-another-crack-fda-approval-for-ra-drug"
            }
        },
        {
            "id": "4142397",
            "type": "article",
            "attributes": {
                "publishOn": "2018-02-01T17:10:49-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: Solid 2017, Soft Sales Guidance",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4142397-eli-lilly-solid-2017-soft-sales-guidance"
            }
        }
    ]
}